Kenvue consensus shapes the week, shares track NYSE performance

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 10:38.

Kenvue (US49177J1025) starts the new week with its shares trading on the NYSE around the high teens, reflecting recent closes near 19 dollars according to MarketBeat data.Kenvue price history on MarketBeat Analyst consensus on the consumer health group remains a key reference point for retail investors tracking the Johnson & Johnson spin-off.

What the consensus shows

Recent analyst coverage compiled by MarketBeat indicates that Kenvue carries a mix of Buy, Hold and Sell ratings, with the average recommendation in the neutral-to-cautious range.Analyst research overview on MarketBeat The aggregated price targets cluster around the low-20-dollar area, offering a modest upside versus the latest NYSE close near 19 dollars.Kenvue price target summary

Position in consumer health

Kenvue operates in the global consumer health segment alongside peers such as Haleon and Sanofi's consumer brands, with the spin-off structure giving it a dedicated NYSE presence.Kenvue competitors list The stock’s recent trading range around 19 dollars per share, as reported by MarketBeat for late June 2026, provides a concrete benchmark for sector comparisons.Kenvue summary page on MarketBeat

The brands behind the stock

Kenvue earns most of its revenue through over-the-counter consumer health products, including well-known names such as Tylenol, Listerine and Neutrogena, according to company information and filings.Kenvue brand portfolio overview The portfolio spans pain relief, oral care, skin health and other daily-use categories across North America, Europe and emerging markets.

Where the Kenvue shares trade

The Kenvue shares (US49177J1025) last closed on the NYSE at 19.14 US dollars on 2026-06-26, with an extended trading indication around 19.03 dollars later that day, based on MarketBeat’s consolidated price data.Detailed KVUE chart data on MarketBeat

This article provides factual information on the Kenvue shares and does not contain investment advice or a recommendation to buy or sell securities. All data points are based on publicly available sources believed to be reliable at the time of review.